Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections
The core objective is to conduct multicentre, multinational, randomised controlled clinical trials to provide scientific evidence of the safety and efficacy of phage therapy, either as monotherapy or in combination with standard treatment, for the management of hard-to-treat bacterial infections. Three projects will each receive €15 million in funding.

Leveraging artificial intelligence for pandemic preparedness and response
This call supports the development of new or the enhancement of existing AI-powered tools, methods, and technologies aimed at improving the safety, efficiency, and effectiveness of medical, societal, or logistical countermeasures. The goal is to prevent, contain, or manage infectious disease outbreaks, or to strengthen the emergency response capabilities of health systems. 5 to 6 projects will be funded with €6–8 million each.

Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential
Only projects focused on advancing existing prophylactic or therapeutic candidates based on antibodies or antibody-derived proteins will be eligible. Candidates must target priority viruses. Projects are expected to include preclinical studies, GMP-grade batch manufacturing, and initial clinical safety testing in humans (first-in-human trials). Approximately €10 million is available for each of 5 projects.

Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)
Projects under this topic should aim to further optimise and scale up existing manufacturing processes for ATMPs. 5 to 6 projects will be funded with €6–8 million each.

Enhancing cell therapies with genomic techniques
Projects are expected to develop customised, genetically modified cells with improved therapeutic performance – for example, greater persistence, targeted effects, and better tolerability. Genome editing techniques must be a central component of the therapeutic approach. 5 to 6 projects will be funded with €6–8 million each.

Advancing cell secretome-based therapies
This topic aims to support projects developing safe, effective, and regulatory-approvable secretome-based therapies derived from human cells. 3 to 4 projects will each receive between €9–13 million in funding.

Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research
Projects should further develop generative AI models for biomedical research and demonstrate their value for personalised treatment approaches. Expected outcomes include robust models based on complex health data, proof of added value in two use cases, and the development of appropriate evaluation methods. 3 to 4 projects will be funded with €15–17 million each.

Facilitating the conduct of multinational clinical studies of orphan devices and/or of highly innovative (“breakthrough”) devices
This topic supports projects conducting multinational clinical studies on medical devices intended for the treatment, diagnosis, or prevention of rare conditions and/or for the development of highly innovative (“breakthrough”) products, including digital and AI-based tools and technologies. Up to 5 projects will be funded with €6–8 million each.

Boosting the translation of biotech research into innovative health therapies
This topic supports early-phase clinical trials (Phase I, II, or I/II) for innovative biotechnology-based therapies developed by SMEs, aiming to bridge the gap between preclinical and clinical development. A total of €80 million is available, with expected project budgets ranging from €4–8 million.